KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE: SGP) announced today the U.S.

GAITHERSBURG, Md., Oct. 5, /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE: SGP) announced today that the U.S.

Schering-Plough Corp.'s asenapine has been cleared for sale as a treatment for schizophrenia and bipolar disorder in adults, U.S.

Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP) today announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.

Corifollitropin alfa, a sustained follicle stimulant, extends options for patients and Schering-Plough's leadership in fertility KENILWORTH, N.J., Dec.